A single-blind, randomized, phase II UK multi-centre study to determine the reactogenicity and immunogenicity of heterologous prime/boost COVID-19 vaccine schedules – stage 2
Latest Information Update: 04 Sep 2023
At a glance
- Drugs AZD 1222 (Primary) ; Elasomeran (Primary) ; NVX CoV 2373 (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Acronyms Com-COV2
- 05 Apr 2023 Results (n=1072) assessing the persistence of immune response to the viral vectored, mRNA and protein-based COVID-19 vaccine platforms used in homologous and heterologous priming combinations published in the Journal of Infection
- 03 Oct 2022 Planned End Date changed from 1 Sep 2022 to 1 Sep 2023.
- 03 Oct 2022 Status changed from completed to recruiting.